Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04101578
Other study ID # 2017YFC0907705
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date February 8, 2017
Est. completion date December 31, 2024

Study information

Verified date August 2021
Source Da, Yuwei, M.D.
Contact yuwei Da, M.D.
Phone 00-86-010-83198492
Email dayuwei1000@163.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study collects the clinical data of myasthenia gravis (MG) patients, assesses outcomes and adverse effects of different treatment regimens, and searches for risk factors of conversion to generalized MG.


Description:

This is a multicenter, observational cohort trial in the real-world clinical setting recruiting MG patients from Neurology Departments of 6 hospitals in different regions of China. Clinical manifestations, laboratory test results, chest imaging and history of thymectomy are recorded. Patients will be classified by clinical manifestation as well as antibody status, and treatment regimens are determined according to the physician's judgment and preferences of the patients. Patients are followed up prospectively on regular to assess the outcomes of treatments and monitor any side effects. Peripheral blood samples are collected annually. Patients' clinical records are uploaded to an online database. The investigators plan to recruit a final sample of 2000 patients for analysis.


Recruitment information / eligibility

Status Recruiting
Enrollment 2000
Est. completion date December 31, 2024
Est. primary completion date June 1, 2023
Accepts healthy volunteers No
Gender All
Age group 15 Years and older
Eligibility Inclusion Criteria: 1. Age >14. 2. Clinical Diagnosis of MG with supporting evidence: 1. unequivocal clinical response to pyridostigmine 2. positive antibody testing 3. decrement >10% in repetitive nerve stimulations study (RNS) . 3. Willingness to sample collection, imaging study and other disease-related examinations and assessments. 4. Patients with informed consent. Exclusion Criteria: 1. History of chronic degenerative, psychiatric, or neurologic disorder other than MG that can produce weakness or fatigue. 2. Age =14 years. 3. Severe anxiety, depression or schizophrenia. 4. Cognitive impairment or mini-mental state examination (MMSE) score =24. 5. Severe systemic illness with life-expectancy less than 4 years. 6. Unwillingness to consent for collection of biological samples. 7. Inability to provide informed consent.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Symptomatic Treatment, Steroids, Immunosuppressive Agents, Plasma Exchange(PE), Intravenous Immunoglobulin(IVIg)
Treatment regimens are determined according to the physician's judgment and preferences of the patients.

Locations

Country Name City State
China Xuan Wu Hospital, Capital Medical University Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Da, Yuwei, M.D.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Conversion rates from ocular to generalized MG at the last visit and risk factors. Ocular MG patients are followed up to determine the ratio of conversion to generalized disease at the end of follow-up. The clinical records will be retrospectively analyzed to search for risk factors of progressing. Baseline, 48 months
Primary Change in Quantitative Myasthenia Gravis (QMG) Scores from Baseline to 48 months. The QMG is a 13-item scale which measures ocular, bulbar, limb function and respiratory function. The total score ranges from 0 (no myasthenic findings) to 39 (maximal myasthenic deficits) obtained by summing the responses to each individual item (None=0, Mild=1, Moderate=2, Severe=3). Baseline, 12 months, 24 months, 36 months, 48 months
Primary Change in MG-specific Activities of Daily Living scale (MG-ADL). The MG-ADL is an 8-item scale to assess symptoms of myasthenia gravis patients obtained by summing the responses to each individual item (Grades: 0,1,2,3). The score ranges from 0 to 24. Baseline,3months, 6 months, 9 months, 12 months, 18 months, 24 months, 30months, 36 months, 42 months, 48 months
Primary The proportion of patients reaching minimal manifestations (MM) or better. Clinical statuses of patients are assessed and categorized according to Myasthenia Gravis Foundation of America (MGFA) postintervention status (PIS). MM or better includes Minimal Manifestation (MM), Pharmacologic Remission (PR) or Complete Remission (CR). 48 months
Secondary Proportion of Patients with Treatment-related Adverse Experiences. Treatment-Related Adverse Events (AEs) are evaluated in patients of different regimens. 3 months, 6 months, 12 months, 24 months, 36 months, 48 months
Secondary Changes in titers of MG antibodies. MG antibodies are detected at enrollment and the titers of antibodies will be monitored annually. Baseline, 12 months, 24 months, 36 months, 48 months
See also
  Status Clinical Trial Phase
Completed NCT05039190 - Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients Phase 3
Recruiting NCT04561557 - Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System Early Phase 1
Completed NCT01727193 - The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy Phase 3
Completed NCT00285350 - Mycophenolate Mofetil in Myasthenia Gravis Phase 3
Recruiting NCT05890833 - The Risk of Falls Index for Patients With Neuromuscular Disorders
Completed NCT05694234 - Influences of Sugammadex on Postoperative Progress in Patients With Myasthenia Gravis Undergoing Video-assisted Thoracoscopic Thymectomy: Retrospective Study
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Not yet recruiting NCT04965987 - Oxaloacetate in Myasthenia Gravis Phase 1
Not yet recruiting NCT05095103 - Immune Profiles in Myasthenia Gravis
Completed NCT02774239 - A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG) Phase 3
Completed NCT02066519 - Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis N/A
Terminated NCT02102594 - Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB) Phase 2
Completed NCT02118805 - Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders
Terminated NCT01828294 - Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis Phase 1
Terminated NCT00727194 - Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis Phase 2
Completed NCT04590716 - Help Build an A.I. Model to Predict Myasthenia Gravis Symptom Patterns and Flares
Recruiting NCT04837625 - Study of Myasthenic Crisis in China
Not yet recruiting NCT01469858 - Perception and Multisensory Integration in Neurological Patients Using fMRI N/A
Completed NCT05408702 - Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes
Completed NCT03205306 - Myasthenia Gravis and Psyche